Eli Lilly's third-quarter report is a strong one by any standard. Revenue beat estimates, the company raised its full-year sales outlook to between $91 billion and $92 billion, up from $85 billion to $87 billion, and its shares rose about 7% on Thursday. Investors have good reason to celebrate. But a column about a company selling weight-loss drugs at this scale should ask who is paying, who is being reached, and what happens when the profits outpace the patients.
The numbers point to demand that is not slowing. Mounjaro's worldwide revenue rose 65% to $10.72 billion, beating the $10.10 billion analysts expected. Zepbound brought in $5.35 billion, up 49%. U.S. revenue climbed 34% to $15.1 billion. Lilly also reported a 63% share of the U.S. obesity and diabetes drug market, compared with Novo's 36.6%. Yet the same report notes a 7% drop in realized U.S. prices, driven primarily by Zepbound, following a drug pricing deal struck with the Trump administration last year. Volume is doing the work that price used to do.
The new obesity pill, Foundayo, is the caveat in this story. Its $184 million in third-quarter sales fell short of analyst forecasts of around $229 million, even though U.S. prescriptions and new patients doubled from the prior quarter. Lilly's CFO said about 4 in 10 patients starting an oral obesity medicine choose Foundayo. That is a respectable share in a market Lilly already dominates, but it also suggests the company's growth still depends on a small number of blockbuster products.
CEO Dave Ricks told CNBC that he estimates only 3% to 10% of eligible patients access obesity care in the U.S., and that the "room for expansion here of this market is dramatic." He is right that expansion is the business plan. Medicare's temporary pilot covering GLP-1s for weight loss, which began in July, is a meaningful step toward access. Still, a company that projects such expansion should be held to account for how that expansion is priced, covered, and shared, not simply praised for its pace.
My recommendation is simple. Regulators and payers should monitor whether the Medicare pilot becomes a durable benefit, and whether lower net prices translate into broader access rather than bigger margins. Lilly's own filing shows it is converting profits into a deal-making spree, including its agreement to buy Merida Biosciences. Shareholders may welcome that. The public should ask for evidence that the money from obesity drugs is reaching the people who need them.